INTRODUCTION {#s1}
============

The programmed death-1 (PD-1)/PD-Ligand 1 (PD-L1) immune checkpoint has been extensively investigated \[[@R1]-[@R5]\]. PD-L1 production by tumor cells is a natural defense of cancer cells against host immune system destruction, downregulating the antitumor activity of immune T (killer) cells \[[@R1], [@R6]-[@R8]\]. Antibodies to PD-L1 and to PD-1 have been shown clinically to have important utility in the management of a variety of malignancies \[[@R9]-[@R15]\].

A non-antibody-based mechanism by which PD-L1 elaboration by tumor cells can be regulated involves thyroid hormone analogues \[[@R16], [@R17]\]. L-thyroxine (T~4~) is the principal product of the thyroid gland and is viewed as prohormone for the major intracellular thyroid hormone, 3,5,3'-triiodo-L-thyronine (T~3~). However, T~4~ has a panel of biological actions at a tumor cell surface receptor on plasma membrane integrin αvβ3 \[[@R18]\]. One of these actions downstream of the receptor is upregulation of transcription of PD-L1 \[[@R16]\]. A derivative of T~4~, tetraiodothyroacetic acid (tetrac), blocks this action of T~4~ initiated at αvβ3. We have proposed that tetrac, modified chemically to limit its actions to the exterior of tumor cells expressing αvβ3 \[[@R19]\], be tested as a non-antibody-based strategy to decrease or eliminate PD-L1 as a cancer cell defense \[[@R16]\].

PD-L1 IN T~4~-TREATED TUMOR CELLS {#s2}
=================================

Thyroid hormone as T~4~ in physiological free concentrations supports cancer cell proliferation and a number of survival pathways in tumor cells \[[@R20]\]. These cancer support actions are initiated by T~4~ at a receptor site on the extracellular domain of integrin αvβ3. While these actions are non-genomic at initiation---that is, they do not directly depend upon the nuclear receptors for thyroid hormone (TRs)---they may culminate downstream in transcription of specific genes \[[@R18]\], certain of which may involve TRs. These downstream effects are mediated by intracellular signal transduction systems, such as MAPK/ERK and PI3K. Unmodified or chemically converted to a nanoparticle, tetrac blocks actions of T~4~, including activation of MAPK and PI3K.

The involvement of ERK1/2 and PI3K in the enhancement of *PD-L1* gene expression \[[@R16], [@R21]\] caused us to search for possible involvement of T~4~ in the regulation of *PD-L1* transcription. Studied *in vitro* in human breast and colon cancer cell lines, *PD-L1* expression was enhanced by T~4~ \[[@R16]\] and complimented by accumulation of tumor cell PD-L1 protein by as much as 2.7-fold. Tetrac chemically bound to a poly lactic-co-glycolic acid (PLGA) nanoparticle, (Nanotetrac, nano-diamino-tetrac (NDAT)), substantially reduced the stimulatory effect of T~4~ on *PD-L1* gene expression and on abundance of cellular PD-L1 protein. In addition to its anti-apoptotic property, PD-L1 may also be a proliferative factor in certain cancer cells \[[@R22]\]. These results support the possibility that circulating host T~4~ is contributing to defensive activation in cancer cells of PD-L1.

The NDAT results indicated the feasibility of using a small molecule to modulate the PD-1/PD-L1 checkpoint by reducing the availability of PD-L1 \[[@R23]\]. This approach would also avoid the systemic adverse effects of PD-L1 antibody \[[@R24], [@R25]\] because actions of NDAT are limited to cancer cells and rapidly dividing endothelial cells that generously express αvβ3.

NEWLY RECOGNIZED ROLES OF INTRACELLULAR PD-L1 AND PD-1 IN T~4~-TREATED CANCER CELLS {#s3}
===================================================================================

Against the background described, it is reasonable to ask whether PD-L1 has clinically undesirable intracellular effects that also may be avoided by downregulating the transcription of *PD-L1* with NDAT or similar compounds. Resveratrol, a stilbene with anticancer properties, can induce p53-dependent apoptosis in cancer cells by a mechanism that involves *nuclear* uptake of cyclooxygenase-2 (COX-2) \[[@R17], [@R26]\]. This was a novel role for COX-2.

Studied in the resveratrol-p53-COX-2 model in tumor cells exposed to T~4~, intracellular PD-L1 was found to be complexed with COX-2 in cytoplasm and no nuclear uptake of p53 and COX-2 occurred \[[@R17]\]. Therefore, resveratrol-induced apoptosis was inhibited. Thus, in addition to its function extracellularly as a ligand of T cell PD-1 at the PD-1/PD-L1 immune checkpoint and thus a defense against immune system destruction of cancer cells, PD-1 has an intracellular role as an inhibitor of inducible COX-2/p53-dependent apoptosis. This function is also a cancer cell survival mechanism for PD-L1. The results raise a set of questions that have not yet been addressed. For example, does the interaction of PD-L1 with inducible COX-2 in T~4~-treated tumor cells alter the function of COX-2 and reduce intracellular content of prostaglandins? Does this interaction model other protein-protein interactions in cytoplasm that are relevant to cancer cell defenses? The proteins could, for example, be signal transducing molecules or hormone-binding proteins such as nuclear thyroid hormone receptors (TRs) or estrogen receptors in cytoplasm.

The possibility that PD-1 has functions in cells other than T and B lymphocytes and macrophages has been suggested in reports from a number of laboratories that PD-1 is expressed by ovarian carcinoma cells \[[@R27]\], melanoma \[[@R28]\], small cell lung carcinoma \[[@R29]\], osteosarcoma cells \[[@R30]\] and murine lung carcinoma cells \[[@R31]\]. Physiological amounts of T~4~ induce expression of *PD-1* mRMA as well as accumulation of PD-1 protein in several human cancer cell lines (HY Lin: unpublished observations). NDAT blocks the action of T~4~ on the PD-1 axis in these cancer cells (Figure [1](#F1){ref-type="fig"}). Such preliminary studies provide no functional basis for the PD-1 response in human tumor cells, but it is known that injured, non-tumoral retinal ganglion cells (RGCs) express PD-1 \[[@R32]\], as do mouse RGCs scheduled to undergo apoptosis \[[@R33]\]. Thus, elaboration of PD-1 in cells other than lymphocytes and macrophages may be related to self-defense, e.g., apoptosis. This possibility requires systematic evaluation in other non-cancer cells.

![T~4~ induces *PD-1* mRMA expression in human colon cancer (HT-29, HCT116 and breast cancer (MDA-MB-231) cells *in vitro*\
Nano-diamino-tetrac (NDAT) inhibits actions of T~4~ that are initiated at plasma membrane integrin αvβ3 and has anticancer activity in the absence of T~4~. In this study, NDAT inhibited stimulatory activity of T~4~ on expression of *PD-1* mRMA and also reduced abundance of *PD-1* mRMA in the absence of T~4~. Materials, including cell lines, and methods used are as previously described \[[@R16]\]. Compared to control, \**p* \<0.05, \*\*\**p* \<0.001; compared to T~4~, alone, \#*p* \<0.05, \#\#\#*p* 0.001.](oncotarget-09-34033-g001){#F1}

OVERVIEW {#s4}
========

That a thyroid hormone analogue such as T~4~ can regulate intracellular concentrations of PD-1 and PD-L1 by a mechanism that is inhibitable by NDAT indicates that T~4~ is indeed biologically active and its activity is manifested via the hormone receptor on integrin αvβ3. T~4~ is the principal ligand of this receptor \[[@R20], [@R34]\], and NDAT at the concentration used is a specific inhibitor of thyroid hormone actions at αvβ3 \[[@R16]\]. The transcription of a large number of genes is regulated by this cell surface hormone receptor \[[@R35]\], and many of these are relevant to tumor cell proliferation, to tumor cell survival anti-apoptotic pathways \[[@R20]\] and to rapidly dividing endothelial cells and angiogenesis \[[@R36], [@R37]\]. We suggest that accumulation of intracellular PD-L1 and PD-1 in cancer cells offers another anti-apoptotic defense for tumor cells that is in a compartment inaccessible to clinically used antibodies to PD-1 and PD-L1 \[[@R23]\]. As noted above, accumulation of PD-L1 may occur in non-cancer cells that are at risk of apoptosis. Another role for PD-L1 involves regulation of angiogenesis \[[@R38]\]. Thus, distinct from their synergy in the function of the PD-1/PD-L1 immune checkpoint, these two moieties have functions as independent proteins. At least in part, these functions are regulated by thyroid hormone as T~4~.

Another issue is that resistance to apoptosis accompanies activation of the immune checkpoint in tumor cells \[[@R39]\]. Accumulation of PD-L1 and PD-1 within tumor cells exposed to T~4~ may be a component of the anti-apoptosis encountered in checkpoint activation.

T~4~ is known to have pro-angiogenic and anti-apoptotic properties \[[@R18]\], and the independent control by T~4~ via αvβ3 of PD-1 and PD-L1 production unrelated to the PD-1/PD-L1 immune checkpoint is consistent with roles already defined for T~4~. While further studies are required to determine how substantial the clinical contributions are of T~4~ to tumor-related angiogenesis and anti-apoptosis, elimination of T~4~ in patients with advanced cancers has shown stabilization of the disease and extended survival \[[@R40]\].
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